Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture

被引:101
作者
Broussau, Sophie [1 ,2 ]
Jabbour, Nadine [1 ]
Lachapelle, Guillaume [1 ]
Durocher, Yves [3 ]
Tom, Rosanne [3 ]
Transfiguracion, Julia [3 ]
Gilbert, Renald [1 ,4 ]
Massie, Bernard [1 ,3 ,5 ]
机构
[1] Conseil Natl Rech Canada, Inst Rech Biotechnol, Grp Vecteurs Genom & Therapie Genique, Montreal, PQ, Canada
[2] Univ Montreal, Fac Med, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada
[3] Conseil Natl Rech Canada, Inst Rech Biotechnol, Grp Technol Cellules Anim, Montreal, PQ H4P 2R2, Canada
[4] Montreal Neurol Inst, Neuromuscular Res Grp, Montreal, PQ, Canada
[5] Univ Quebec, Inst Armand Frappier, Inst Natl Res Sci, Laval, PQ, Canada
关键词
D O I
10.1038/sj.mt.6300383
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We have developed new packaging cell lines (293SFPacLV) that can produce lentiviral vectors (LVs) in serum-free suspension cultures. A cell line derived from 293SF cells, expressing the repressor (CymR) of the cumate switch and the reverse transactivator (rtTA2S-M2) of the tetracycline (Tet) switch, was established first. We next generated clones stably expressing the Gag/Pol and Rev genes of human immunodeficiency virus-1, and the glycoprotein of vesicular stomatitis virus (VSV-G). Expression of Rev and VSV-G was tightly regulated by the cumate and Tet switches. Our best packaging cells produced up to 2.6 x 10(7) transducing units (TU)/ml after transfection with the transfer vector. Up to 3.4 x 10(7) TU/ml were obtained using stable producers generated by transducing the packaging cells with conditional-SIN-LV. The 293SFPacLV was stable, as shown by the fact that some producers maintained high-level LV production for 18 weeks without selective pressure. The utility of the 293SF-PacLV for scaling up production in serum-free medium was demonstrated in suspension cultures and in a 3.5-L bioreactor. In shake flasks, the best packaging cells produced between 3.0 and 8.0 x 10(6) TU/ml/day for 3 days, and the best producer cells, between 1.0 and 3.4 x 10(7) TU/ml/day for 5 days. In the bioreactor, 2.8 liters containing 2.0 x 106 TU/ml was obtained after 3 days of batch culture following the transfection of packaging cells. In summary, the 293SF-PacLV possesses all the attributes necessary to become a valuable tool for scaling up LV production for preclinical and clinical applications.
引用
收藏
页码:500 / 507
页数:8
相关论文
共 44 条
[1]   A SELECTABLE BIFUNCTIONAL BETA-GALACTOSIDASE--PHLEOMYCIN-RESISTANCE FUSION PROTEIN AS A POTENTIAL MARKER FOR EUKARYOTIC CELLS [J].
BARON, M ;
REYNES, JP ;
STASSI, D ;
TIRABY, G .
GENE, 1992, 114 (02) :239-243
[2]  
Blomer U, 1997, J VIROL, V71, P6641
[3]  
BOUNKONG S, 2002, J MACHINE LEARNING R, V1, P1
[4]   VESICULAR STOMATITIS-VIRUS G GLYCOPROTEIN PSEUDOTYPED RETROVIRAL VECTORS - CONCENTRATION TO VERY HIGH-TITER AND EFFICIENT GENE-TRANSFER INTO MAMMALIAN AND NONMAMMALIAN CELLS [J].
BURNS, JC ;
FRIEDMANN, T ;
DRIEVER, W ;
BURRASCANO, M ;
YEE, JK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (17) :8033-8037
[5]   SPECIFIC INTERACTION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS REV PROTEIN WITH A STRUCTURED REGION IN THE ENV MESSENGER-RNA [J].
COCHRANE, AW ;
CHEN, CH ;
ROSEN, CA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (03) :1198-1202
[6]   A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors [J].
Cockrell, Adam S. ;
Ma, Hong ;
Fu, Kailing ;
McCown, Thomas J. ;
Kafri, Tal .
MOLECULAR THERAPY, 2006, 14 (02) :276-284
[7]   Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line [J].
Corbeau, P ;
Kraus, G ;
WongStaal, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) :14070-14075
[8]   PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions [J].
Corbeil-Girard, LP ;
Klein, AF ;
Sasseville, AMJ ;
Lavoie, H ;
Dicaire, MJ ;
Saint-Denis, A ;
Pagé, M ;
Duranceau, A ;
Codère, F ;
Bouchard, JP ;
Karpati, G ;
Rouleau, GA ;
Massie, B ;
Langelier, Y ;
Brais, B .
NEUROBIOLOGY OF DISEASE, 2005, 18 (03) :551-567
[9]  
Côté J, 1998, BIOTECHNOL BIOENG, V59, P567, DOI 10.1002/(SICI)1097-0290(19980905)59:5<567::AID-BIT6>3.3.CO
[10]  
2-Z